Autolus Therapeutics Reports First Quarter 2022 Financial Results and Operational Progress
May 05, 2022 07:00 ET
|
Autolus Therapeutics plc
LONDON, May 05, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics announces retirement of chief financial officer and succession plan
January 10, 2022 07:01 ET
|
Autolus Therapeutics plc
- Andrew J. Oakley to retire in March 2022 - Dr. Lucinda Crabtree to succeed him as chief financial officer LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a...